Objective: study cytogenetic risk groups and the complete remission rate in acute myelogenous leukemia patients. Patients and method: 104 patients with acute myelogenous leukemia (AML) were studied. Cytogenetic analysis and PCR testing to detect PML/RARo, AML1/ETO, CBFbeta/MYH1 fusion genes was done before were taken the induction chemotherapy and the complete remission was estimated. Results and conclusions: The rate of favorable group was 51.9 percent, intermedia: 35.6 percent and unfavorable: 12.5 percent. The complete remission rate of favorable group was: 81 percent, intermediate: 59 percent and unfavorable: 16 percent.